June 18, 2018

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Addgene keeps flow of CRISPR plasmids fast and affordable

Credit: Mary Ann Liebert, Inc., publishers
× close
Credit: Mary Ann Liebert, Inc., publishers

As a key global enabler of the revolutionary genome editing technology known as CRISPR, the nonprofit organization Addgene has made available more than 100,000 CRISPR plasmids (circular DNA fragments) to 3,400 laboratories worldwide. The origins, goals, global reach, and success of Addgene in democratizing CRISPR, which his dramatically changing medical research, are described in a Perspective article published in The CRISPR Journal.

"Enabling the Rise of a CRISPR World" is the collaboration of coauthors Caroline LaManna, Addgene, Cambridge, MA and Rodolphe Barrangou, North Carolina State University, Raleigh and Editor-in-Chief of The CRISPR Journal. The authors discuss the critical need for fast, affordable, global access to the essential tools for performing genome editing. Addgene was already serving as a nonprofit repository where scientists could store plasmids and make them available for worldwide distribution when the tools for CRISPR editing were being developed. The ensuing demand for open access to CRISPR technologies and deposition of CRISPR plasmids and next-generation CRISPR tools has helped the technology to advance and flourish.

"Addgene has played a major role in the exciting democratization of CRISPR, delivering the tools for groundbreaking gene editing research to investigators in every corner of the globe," says Kevin Davies, Ph.D., Executive Editor of The CRISPR Journal. "This timely commentary is another example of how The CRISPR Journal is making good on its pledge to become the voice of the international CRISPR community."

More information: Caroline M. LaManna et al, Enabling the Rise of a CRISPR World, The CRISPR Journal (2018). DOI: 10.1089/crispr.2018.0022

Load comments (0)